β-endorphins Plasma Level is Higher in Lean Polycystic Ovary Syndrome (PCOS) Women

 

 Buy Article Permissions and Reprints

Abstract

Aim: The evaluation the β-endorphin plasma levels in lean women with polycystic ovary syndrome as well as in women without this disorder. The associations between β-endorphins and other laboratory parameters were also investigated.

Materials and methods: 31 women lean, defined as women with normal range body mass index, 15 with polycystic ovary syndrome and 16 without this disorder were included to the study. In all the patients the level of β-endorphins was measured. Also the diagnostic laboratory profile including hormone assessment was made in all patients.

Results: There were significant differences in β-endorphin levels between the 2 groups. The β-endorphin level was higher in the polycystic ovary syndrome group compared to the healthy controls (15.5±4.37 pg/ml vs. 6.9±2.47 pg/ml, p<0.0001). The β-endorphin levels positively correlated with cortisol at 8 am (R=0.632, p=0.011) and negatively correlated with sex hormone binding globuline (R=0.518, p=0.0478) in polycystic ovary syndrome group. Increase in β-endorphin level of 1 pg/ml was associated with an increase of cortisol at 8 am level of 1.134 µg/dl and decrease of sex hormone binding globuline of 0.948 nmol/l in polycystic ovary syndrome group.

Conclusion: Our study showed that the levels of β-endorphins were significantly higher in lean patients with polycystic ovary syndrome than in lean controls. Moreover, β-endorphins levels were found to be correlated with other hormonal parameters. In this respect, β-endorphins may play a role in polycystic ovary syndrome pathophysiology.

• References

• 1 Eyvazzadeh AD, Pennington KP, Pop-Busui R et al. The role of the endogenous opioid system in polycystic ovary syndrome. Fertility and Sterility 2009; 92: 1-12
  CrossrefPubMedSearch in Google Scholar
• 2 Azziz R. Diagnosis of polycystic ovarian syndrome: The rotterdam Criteria are premature. JCEM 2006; 91: 781-785
  PubMedSearch in Google Scholar
• 3 Azziz R, Carmina E, Dewailly D et al. The Androgen Exsess and PCOS Society criteria for the polycystic ocary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-488
  CrossrefPubMedSearch in Google Scholar
• 4 Ahmed MI, Duleba AJ, El Shahat O et al. Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. Human Reproduction 2008; 23: 2564-2569
  CrossrefPubMedSearch in Google Scholar
• 5 Guido M, Romualdi D, Lanzone A. Role of opioid antagonists in the treatment of women with glucoregulation Abnormalities. Curr Pharm Des 2006; 12: 1001-1012
  CrossrefPubMedSearch in Google Scholar
• 6 Marshall JC, Eagleson CA. Neuroendocrine aspects of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28: 295-324
  CrossrefPubMedSearch in Google Scholar
• 7 Arora S. Role of neuropeptides in appetite regulation and obesity – a review. Neuropeptides 2006; 40: 375-401
  CrossrefPubMedSearch in Google Scholar
• 8 Barbieri RL, Smith S, Ryan J. The role of hyperandrogenemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988; 50: 197-210
  PubMedSearch in Google Scholar
• 9 Frager MS, Pieper DR, Tonetta SA et al. Pituitary gonadotropin-releasing hormone receptors. Effects of castration, steroid replacement and the role of gonadotropin-releasing hormone in modulating receptors in rat. J Clin Invest 1981; 67 (615) 623
  PubMedSearch in Google Scholar
• 10 Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 1993; 39: 1-16
  CrossrefPubMedSearch in Google Scholar
• 11 Pasquali R, Vicennati V. Activity of the hypothalamic-pituitary-adrenalaxis in different obesity phenotypes. Int J Obes Relat Metab Disord 2000; 24: S47-S49
  CrossrefPubMedSearch in Google Scholar
• 12 http: //www.phoenixpeptide.com/catalog/repository/QCdata_RIK/RK-022-14.pdf
  PubMed
• 13 Wortsman J, Wehrenberg WB, Gavin JR et al. Elevated levels of plasma betaendorphin and melanocyte stimulating hormone in the polycystic ovary syndrome. Obstet Gynecol 1984; 63: 630-635
  PubMedSearch in Google Scholar
• 14 Givens JR, Wiedman E, Andersen RN et al. β-endorphin and β-lipotropin plasma levels in hirsute women correlation with body weight. J Clin Metab 1980; 50: 975-976
  CrossrefPubMedSearch in Google Scholar
• 15 Genazzani AR, Facchinetti F, Petraglia F et al. Hyperendorphinemia in obese children and adolescents. J Clin Metab 1986; 62: 36-40
  CrossrefPubMedSearch in Google Scholar
• 16 Lackey BR, Gray SL, Henricks DM et al. The insulin-like growth factor(IGF) system and gonadotropin regulation: actions and interactions. Cytokine Growth Factor Rev 1999; 10: 201-217
  CrossrefPubMedSearch in Google Scholar
• 17 Giugliano D, Ceriello A, Salvatore T et al. b-Endorphin infusion restores acute insulin response to glucose in type-II diabetes mellitus. J Clin Endocrinol Metab 1978; 64: 944-948
  PubMedSearch in Google Scholar
• 18 Feldmann M, Kiser RS, Unger RH et al. β-endorphin and the endocrine pancreas. Studies in healthy and diabetic human beings. N Engl J Med 1983; 308: 349-353
  CrossrefPubMedSearch in Google Scholar
• 19 Reid RL, Yen SSC. Beta-endorphin stimulates the secretion of insulinand glucagon in humans. J Clin Endocrinol Metab 1981; 52: 592-594
  CrossrefPubMedSearch in Google Scholar
• 20 Lanzone A, Fulghesu AM, Fortini A et al. Effect of opiate receptor blockade on the insulin response to oral glucose load in polycystic ovarian disease. Hum Reprod 1991; 6: 1043-1049
  PubMedSearch in Google Scholar
• 21 Nestler JE, Jakubowicz DJ, De Vrgas AF et al. Insulin stimulates testosterone biosynthesis by human thecal cell from women with polycystic ovary syndrome by activating its own receptor and using inositoglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83: 2001-2005
  CrossrefPubMedSearch in Google Scholar
• 22 Fulghesu AM, Ciampelli M, Fortini A et al. Effect of opioid blockade on insulin metabolism in polycysticovarian disease. Hum Reprod 1995; 10: 2253-2257
  CrossrefPubMedSearch in Google Scholar
• 23 Dunaif A, Segal KR, Futterwiet W. Profound peripheral insulin resistance, independent of obesity in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174
  CrossrefPubMedSearch in Google Scholar
• 24 Yen SSC, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease, hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970; 30: 435-442
  CrossrefPubMedSearch in Google Scholar
• 25 Veldhuis JD, Rogol AD, Samojlik E et al. Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man. J Clin Invest 1985; 74: 47-55
  PubMedSearch in Google Scholar
• 26 Lanzone A, Fulghesu AM, Cucinelli F et al. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion. J Clin Endocrinol Metab 1995; 80: 3501-3506
  PubMedSearch in Google Scholar
• 27 Petraglia F, Di Meo G, De Leo V et al. Plasma B-endorhpin levels in anovulatory states: changes after treatments for the induction of ablation. Fertil Steril 1986; 45: 185-190
  PubMedSearch in Google Scholar
• 28 Aleem FA, McIntosh T. Elevated plasma levels of β-endorphin in a group of women with polycystic ovarian disease. Fertil Steril 1984; 42: 686-689
  PubMedSearch in Google Scholar
• 29 Carmina E, Ditkoff EC, Malizia G et al. Increased circulating levels of immunoreactive b-endorphin in polycystic ovary syndrome is not caused by increased pituitary secretion. Am J Obstet Gynecol 1992; 167: 1819-1824
  CrossrefPubMedSearch in Google Scholar
• 30 Nestler JE, Powers LP, Matt DW et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-89
  CrossrefPubMedSearch in Google Scholar
• 31 Prelević GM, Würzburger MI, Balint-Perić L et al. 24-h serum cortisol profiles in women with polycystic ovary syndrome. Gynecol Endocrinol 1993; 7: 179-184
  CrossrefPubMedSearch in Google Scholar
• 32 Lobo RA, Granger LR, Paul WL et al. Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome. Am J Obstet Gynecol 1983; 145: 496-503
  CrossrefPubMedSearch in Google Scholar
• 33 Fruzzetti F, Bersi C, Parrini D et al. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril 2002; 77: 936-944
  CrossrefPubMedSearch in Google Scholar
• 34 Tropeano G, Lucisano A, Liberale I et al. Insulin, C-peptide, androgens, and beta-endorphin response to oral glucose in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1994; 78: 305-309
  PubMedSearch in Google Scholar
• 35 Mansson M, Holte J, Landin-Wilhelmsen K et al. Women with polycycstic obary syndrome are often depressed or anxious – a case control study. Psychoneuroendocrinology 2008; 33: 1132-1138
  CrossrefPubMedSearch in Google Scholar
• 36 Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycyctsic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2011; 26: 2442-2251
  CrossrefPubMedSearch in Google Scholar